Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
- Conditions
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT04515524
- Locations
- 🇻🇳
Regeneron Study Site, Hue, Thua Thien-Hue, Vietnam
Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT04506645
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Belgium
🇧🇪Ghent University, Ghent, Belgium
Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04491838
- Locations
- 🇧🇪
Regeneron Study Site, Antwerpen, Belgium
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT04465487
- Locations
- 🇺🇸
Angeles Clinic and Research Institute - Clinic/Outpatient Facility, Los Angeles, California, United States
🇺🇸H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 3303
- Registration Number
- NCT04452318
- Locations
- 🇷🇴
Regeneron Study Site, Bucharest, Romania
🇺🇸Regeneron Study Site 2, Bronx, New York, United States
🇺🇸Regeneron Study Site 3, Chicago, Illinois, United States
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
- Conditions
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT04442269
- Locations
- 🇬🇧
Regeneron Study Site, Bradford, West Yorkshire, United Kingdom
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
- Conditions
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 660
- Registration Number
- NCT04429503
- Locations
- 🇭🇺
Regeneron Study Site 1, Pecs, Baranya, Hungary
🇬🇧Regeneron Study Site, London, United Kingdom
🇺🇸Regeneron Study Site 2, San Antonio, Texas, United States
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 10078
- Registration Number
- NCT04425629
- Locations
- 🇷🇴
Regeneron Study Site, Bucuresti, Romania
🇺🇸Regeneron Study Site 1, Downers Grove, Illinois, United States
🇺🇸Regeneron Study Site 3, Long Beach, California, United States
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2252
- Registration Number
- NCT04426695
- Locations
- 🇷🇴
Regeneron Study Site, Bucuresti, Romania
🇲🇽Regeneron Study Site 1, Mérida, Mexico
🇲🇽Regeneron Study Site 2, Mérida, Mexico
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 133
- Registration Number
- NCT04417894
- Locations
- 🇵🇱
Regeneron Study Site, Wroclaw, Poland